Influenza A virus-IN-1 is a dihydropyrrolidones derivative and is a potent inhibitor against wide subtypes of influenza A virus (IAV) with IC50 values from 3.11 μM to 7.13 μM. Influenza A virus-IN-1 efficiently inhibits replication of IAV, up-regulates the expression of key antiviral cytokines IFN-β and antiviral protein MxA.
Influenza A virus-IN-1 (compound 5-2; 5-40 μM; 24 hours; MDCK cells) treatment significantly decreases the yields of influenza viral NP in a dose-dependent manner. And the expression level of NP protein could also be restrained in a dose-dependent manner[1].
Influenza A virus-IN-1 (compound 5-2) treatment reduces influenza HA mRNA expression at all three time points[1].
Influenza A virus-IN-1 (compound 5-2) could efficiently inhibit replication of IAV and suppress the production of the NDAPH oxidase NOX1 in MDCK cells[1].
References:
[1]. Teng Liu, et al. Discovery of Dihydropyrrolidones as Novel Inhibitors Against Influenza A Virus. Eur J Med Chem. 2020 Aug 1;199:112334.